Cysticercosis Treatment Market: Introduction
· Cysticercosis is a parasitic tissue infection caused by larval cysts of the tapeworm. These larval cysts infection affects the brain, muscle, and other tissues. Humans can become infected by T. saginata (beef tapeworm) or T. asiatica. Moreover, infection through the T. solium tapeworm occurs when a person eats raw or undercooked, infected pork.
Read Report Overview - https://www.transparencymarketresearch.com/cysticercosis-treatment-market.html
· Infections are usually treated with anti-parasitic drugs in combination with anti-inflammatory drugs
· Most individuals with cysticercosis have nervous system involvement (neurocysticercosis). Ophthalmic cysticercosis arises when cysts form in the eyes. It occurs in around 1% to 3% of cysticercosis cases.
· Cysticercosis is spread by contact with tapeworm-infected human faeces. Contaminated food, water, and dirty hands are all sources. Cysticercosis can cause lumps under the skin. Headache and seizure may occur when it spreads to the brain or spinal cord. The tapeworm may exit the body on its own. In some cases drugs are required and sometimes, surgery may be needed.
Cysticercosis Treatment Market: Key Drivers, Restraints
· Rise in cases of protozoan infections worldwide and a lack of sanitation practices in some developing countries are estimated to propel the cysticercosis treatment market during the forecast period
· Human cysticercosis is found worldwide; cysticercosis is most often found in rural areas of developing countries with poor sanitation, where pigs roam freely and eat human feces.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2215
· According to the International Journal of Surgery, Neurocysticercosis (NCC) is the most common parasitic infestation of the brain, and it is estimated that nearly 50 million people worldwide suffer from this disease. Around, 50,000 individuals with NCC die each year due to the disease.
· Major prevalence of the disease is projected to boost the market at a rapid pace during the forecast period
· Rise in adoption of cysticercosis treatment in emerging economies such as China and India is expected to offer considerable opportunities for the global cysticercosis treatment market
· However, higher cost of research & development and high frequency of adverse reactions, owing to the body’s inflammatory reaction to the dying parasites, are key factors restraining the global cysticercosis treatment market
Asia-Pacific to Capture Major Share of Global Cysticercosis Treatment Market
· Based on region, Asia Pacific is expected to hold a prominent share due to a rise in cases of protozoan infections, developing healthcare facilities, and presence of generic companies in the region. In Asia (including China, Southeast Asia, and India), 10% to 20% of individuals suffer from the disease.
· For instance, as per the data published by the International Journal of Surgery, in south India, more than 50,000 people reported that NCC was the cause of nearly a third of active epilepsy in the public. In India, there are one million patients with active epilepsy due to NCC.
· North America is estimated to account for the second-largest segment of the global cysticercosis treatment market during the forecast period, followed by Europe, owing to the high diagnosis rate and presence of sophisticated medical facilities in order to maximize the treatment effectiveness for patient and increase in focus on research and development activity
Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2215
Key Players Operating in Global Cysticercosis Treatment Market
Major players operating in the global cysticercosis treatment market are listed below:
· Cipla Inc
· GlaxoSmithKline plc
· Bayer AG
· Teva Pharmaceuticals Industries Ltd
· Zydus Cadila
· Amneal Pharmaceuticals LLC
· Strides Pharma Science Limited
· Taj Pharmaceuticals Limited
· Edenbridge Pharmaceuticals, LLC
· Others
